Arbitan 75 mg (Tablet)
Unit Price: ৳ 6.02 (3 x 10: ৳ 180.60)
Strip Price: ৳ 60.20
Medicine Details
| Category | Details |
|---|---|
| Generic | Irbesartan |
| Company | Opsonin pharma ltd |
| Also available as |
Indications
- Treatment of essential hypertension
- Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus
Pharmacology
- Angiotensin II receptor antagonist
- Blocks vasoconstricting and aldosterone-secreting effects of angiotensin II
Dosage & Administration
- Usual initial and maintenance dose of 150 mg once daily for adults
- Can be taken with or without food
- Consideration for initial therapy with 75 mg in haemodialysed patients and elderly over 75 years
- Dose adjustment not usually necessary for the elderly
- Not recommended for use in children and adolescents
Interaction
- Risk of hypotension with prior treatment using high dose diuretics
- Concomitant use of potassium-sparing diuretics and potassium supplements not recommended
- Caution with concomitant administration of lithium
- Attenuation of antihypertensive effect with simultaneous administration of non-steroidal anti-inflammatory drugs
Contraindications
- Concomitant use with aliskiren in patients with diabetes and renal impairment (GFR <60 ml/min)
- Pregnancy
Side Effects
- Diarrhoea
- Fatigue
- Dyspepsia or heartburn
- Dizziness
- Orthostatic hypotension
- Nausea
- Vomiting
- Musculoskeletal pain
- Thrombocytopaenia
- Hyperkalaemia
- Elevated serum creatinine
Pregnancy & Lactation
- Contraindicated in second and third trimesters of pregnancy
- Preferably not used during first trimester of pregnancy
- Contraindicated during lactation
- Not recommended for use in lactating rats
Precautions & Warnings
- Special caution for patients with renal artery stenosis, intravascular volume depletion, aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy
- Lower starting dose recommended for patients undergoing haemodialysis
- No dosage adjustment necessary in patients with mild to moderate hepatic impairment
- Close monitoring of serum potassium in patients at risk of hyperkalaemia
Use in Special Populations
- No dosage adjustment necessary in patients with impaired renal function
- Lower starting dose recommended for haemodialysis patients
- No clinical experience in patients with severe hepatic impairment
- Effects not uniform across all subgroups in hypertensive patients with type 2 diabetes and renal disease
- Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy
Overdose Effects
- Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity
- Expected manifestations include hypotension, tachycardia, and bradycardia
- No specific information available on the treatment of overdosage with Irbesartan
- Suggested measures include induction of emesis, gastric lavage, and activated charcoal
Therapeutic Class
- Angiotensin-II receptor blocker
Storage Conditions
- Store in a cool and dry place, protected from light